Rachel Zebo
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)Bristol-Myers Squibb (Sweden)(SE)
Publications by Year
Research Areas
Pancreatic function and diabetes, Hormonal Regulation and Hypertension, Pharmacogenetics and Drug Metabolism, Diabetes Treatment and Management, Peroxisome Proliferator-Activated Receptors
Most-Cited Works
- → Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119(2014)45 cited
- → Discovery of azetidinone acids as conformationally-constrained dual PPARα/γ agonists(2008)37 cited
- → Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1)(2011)28 cited
- → Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)(2014)23 cited
- → The Dual Peroxisome Proliferator-Activated Receptor α/γ Activator Muraglitazar Prevents the Natural Progression of Diabetes in db/db Mice(2007)17 cited
- → Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3′-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor(2017)